• HR-positive and HER2-negative advanced breast cancer in combination with hormonal therapy• Monotherapy for advanced HR-positive and HER2-negative breast cancer• Adjuvant therapy for high-risk, early-stage HR-positive, HER2-negative and lymph node positive breast cancer in combination with hormonal therapy. Here, ERBB2 is linked to breast carcinoma.